ArticleTherapeutic advances in gastroenterology2011
Should quinolones come first in Helicobacter pylori therapy?
Article in Therapeutic advances in gastroenterology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 57 citations in OpenAlex.
- Can the treatment duration be shortened in bismuth-containing therapies for Helicobacter pylori eradication?The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2019Trial
- Seven-day triple therapy is a better choice for Helicobacter pylori eradication in regions with low antibiotic resistance.World journal of gastroenterology · 2015Trial
- A Randomized Controlled Study Comparing Reverse Hybrid Therapy and Standard Triple Therapy for Helicobacter pylori Infection.Medicine · 2015Trial
- A comparative study of the effect of 10-day esomeprazole containing levofloxacin versus clarithromycin sequential regimens on the treatment of Iranian patients withIndian journal of pharmacologyTrial
- Biological Effects of Quinolones: A Family of Broad-Spectrum Antimicrobial Agents.Molecules (Basel, Switzerland) · 2021Review
- Revisiting Therapeutic Strategies forMolecules (Basel, Switzerland) · 2021Review
- Colchicine intoxication in familial Mediterranean fever patients using clarithromycin for the treatment of Helicobacter pylori: a series of six patients.Rheumatology international · 2018Article
- Update on the first-line treatment forBiomarker research · 2017Review
- Efficacy and Safety of the Triple Therapy Containing Ilaprazole, Levofloxacin, and Amoxicillin as First-Line Treatment inGastroenterology research and practice · 2017Article
- Review article: the global emergence of Helicobacter pylori antibiotic resistance.Alimentary pharmacology & therapeutics · 2016Review
- Role of Helicobacter pylori infection in gastric carcinogenesis: Current knowledge and future directions.World journal of gastroenterology · 2015Review
- Efficacy of levofloxacin, amoxicillin and a proton pump inhibitor in the eradication of Helicobacter pylori in Brazilian patients with peptic ulcers.Clinics (Sao Paulo, Brazil) · 2015Article
- Clarithromycin vs. Gemifloxacin in Quadruple Therapy Regimens for Empiric Primary Treatment of Helicobacter pylori Infection: A Randomized Clinical Trial.Middle East journal of digestive diseases · 2015Article
- Treatment of Helicobacter pylori infection: Past, present and future.World journal of gastrointestinal pathophysiology · 2014Review
- Management of Helicobacter pylori infection in Latin America: a Delphi technique-based consensus.World journal of gastroenterology · 2014Article
- Helicobacter pylori eradication in West Asia: a review.World journal of gastroenterology · 2014Review
- Treatment of Helicobacter pylori infection: meeting the challenge of antimicrobial resistance.World journal of gastroenterology · 2014Review
- Attempts to enhance the eradication rate of Helicobacter pylori infection.World journal of gastroenterology · 2014Review
- Eradication of Helicobacter pylori infection.The Kaohsiung journal of medical sciences · 2014Review
- Eradication of Helicobacter pylori infection: which regimen first?World journal of gastroenterology · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
New generations of fluoroquinolones, like levofloxacin and moxifloxacin, exhibit a broad-spectrum activity against Gram-positive and Gram-negative bacteria, and have been successfully introduced into the treatment of Helicobacter pylori infection. Based on a large body of evidence, current guidelines recommend the use of levofloxacin- or moxifloxacin-containing proton-pump inhibitor (PPI) triple therapies in second-line or rescue treatment of H. pylori infection. The efficacy of standard PPI triple therapies has substantially declined during the last decade, mainly due to increasing resistance against the key antibiotics clarithromycin and metronidazole. Therefore, alternative strategies for first-line therapy of H. pylori infection have been evaluated in a considerable number of clinical trials including sequential regimens, nonbismuth quadruple regimens, and quinolone-containing PPI triple therapy regimens. The aim of this paper is to summarize the current body of evidence of levofloxacin- and moxifloxacin-containing regimens in first-line treatment of H. pylori infection, and to discuss the risks and benefits of these strategies in the light of increasing resistance of H. pylori to quinolones.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.